Shares of Veru Inc. VERU were up 20% after it announced on Monday that the FDA had granted Fast Track designation to the phase III registration study on its breast cancer candidate, enobosarm. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback